MACCLESFIELD, England, November 19 /PRNewswire-FirstCall/ -- Cyprotex are proud to announce the introduction in their facilities of one of the most sensitive ion trap and triple quadrupole instruments in the industry.
The QTRAP(R) 5500 LC-MS/MS offers unparalleled sensitivity and impressive speed by uniting the world's most sensitive triple quadrupole with the world's most sensitive and fastest scanning linear ion trap. It combines exceptional quantitative and qualitative analytical potential with no sacrifice in performance for either capability, and allows accurate and precise ion detection over a wide dynamic range.
The introduction of the QTRAP(R) 5500 is part of Cyprotex's expansion of our bioanalytical facility and will enable us to offer a comprehensive bioanalytical method development and validation service as well as an enhanced and highly sensitive metabolite profiling and identification service. The instrument will increase the likelihood of detecting poorly sensitive molecules which are problematic in conventional LC-MS/MS systems.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the purchase of the new QTRAP(R) 5500 LC-MS/MS, "Cyprotex will be able to deliver a superior bioanalytical service which will set us apart from many of our competitors. This state of the art technology allows highly sensitive and accurate analysis giving us the very best chance of successfully detecting and quantifying our customers' molecules."
Ian Clarke, Applied Biosystems' Country Commercial Leader UK & Ireland, comments, "The QTRAP(R) 5500 LC-MS/MS has only recently been launched and Cyprotex are the first company in the UK to benefit from this next generation technology. This addition to their facility will greatly enhance Cyprotex's bioanalytical service enabling their customers to access the most sensitive ion trap LC-MS/MS instruments in the industry."
http://www.cyprotex.com For further information: Cyprotex PLC Helen Gill PhD, Product Development Manager Tel: +44-1625-505-100 email@example.com
|SOURCE Cyprotex Discovery Ltd|
Copyright©2008 PR Newswire.
All rights reserved